Ocugen, Inc.
$471.41M- Market cap
- $461.19M
- Debt
- +$28.79M
- Cash
- −$18.57M
Capital structure 94% equity / 6% debt · EV / Revenue 106.82x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $461.19M · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2026 · Mkt cap
Decision snapshot: OCGN stock price at discount vs ROIV $1.36 current versus $39.75 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROIV's multiple
Implied fair value · at OCGN's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OCGN FY 2025 (ended Dec 31, 2025) · ROIV FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 106.82x
Capital structure 98% equity / 2% debt · EV / Revenue 2584.97x
ROIV carries the larger enterprise value at $21.35B against $471.41M; OCGN trades on the lower EV / Revenue multiple (106.82x vs 2584.97x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
OCUGEN, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-2.37x
0.09x
Net debt / EBITDA
Leverage against operating earnings
-0.16x
24.52x
Cash and equivalents
Liquid reserves on the balance sheet
$18.57M
$4.29B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
IOVANCE BIOTHERAPEUTICS, INC.
OCGN vs IOVA
bluebird bio, Inc.
OCGN vs BLUE
BioNTech SE
OCGN vs BNTX
Moderna, Inc.
OCGN vs MRNA
Legend Biotech Corp
OCGN vs LEGN
Arcturus Therapeutics Holdings Inc.
OCGN vs ARCT
Revolution Medicines, Inc.
OCGN vs RVMD
INCYTE CORP
OCGN vs INCY
Sarepta Therapeutics, Inc.
OCGN vs SRPT
EXELIXIS, INC.
OCGN vs EXEL
VERTEX PHARMACEUTICALS INC / MA
OCGN vs VRTX
$28.79M
$412.94M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.